Screener
ANI Pharmaceuticals ANIP Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfOtherLongTermDebt.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Acquisition of property and equipment, net | (9,128) | (6,488) |
| Net Cash and Cash Equivalents Used in Investing Activities | (14,378) | (26,755) |
| Cash Flows From Financing Activities | ||
| Principal payments on borrowings | (8,125) | (4,062) |
| Series A convertible preferred stock dividends paid | — | (813) |
| Proceeds from stock option exercises and ESPP purchases | 2,510 | 3,776 |
| Treasury stock purchases for restricted stock vests | (20,568) | (10,554) |
| Payment of Novitium Contingent Consideration | (80) | — |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's debt repayments?
- ANI Pharmaceuticals (ANIP) reported debt repayments of $4.06M in Q2 2026.
- How has ANI Pharmaceuticals's debt repayments changed year-over-year?
- ANI Pharmaceuticals's debt repayments increased by 100.0% year-over-year, from $2.03M to $4.06M.
- What is the long-term trend for ANI Pharmaceuticals's debt repayments?
- Over 4 years (2021 to 2025), ANI Pharmaceuticals's debt repayments has grown at a -100.0% compound annual growth rate (CAGR), from $200.15M to $0.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about ANI Pharmaceuticals's debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude